Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001876824 | SCV002120888 | uncertain significance | Ataxia-telangiectasia syndrome | 2022-06-15 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ATM protein function. This variant has not been reported in the literature in individuals affected with ATM-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces leucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 3035 of the ATM protein (p.Leu3035Val). |
| Ambry Genetics | RCV002370374 | SCV002685951 | uncertain significance | Hereditary cancer-predisposing syndrome | 2020-02-21 | criteria provided, single submitter | clinical testing | The p.L3035V variant (also known as c.9103C>G), located in coding exon 62 of the ATM gene, results from a C to G substitution at nucleotide position 9103. The leucine at codon 3035 is replaced by valine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |